Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide (brand name Ozempic) and tirzepatide (brand name Mounjaro) are both prescription medications that activate appetite-suppressing hormonal pathways in the brain, yet they operate through fundamentally different mechanisms. Clinical trials show tirzepatide produces numerically greater weight loss in certain patient populations, while semaglutide remains the more extensively studied option across diverse demographics. PlexusDx offers both compounded versions of these medications, allowing patients to access personalized therapy without insurance barriers.

How Semaglutide and Tirzepatide Work Differently

Semaglutide activates the glucagon-like peptide-1 (GLP-1) receptor, a single hormonal pathway that signals fullness to the hypothalamus and slows gastric emptying. Tirzepatide, by contrast, is a dual-action medication that stimulates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously. This dual-pathway activation means tirzepatide engages two distinct appetite and metabolism-regulating systems in the brain, which some research suggests may contribute to enhanced weight reduction outcomes in certain individuals.

The GIP receptor pathway influences satiety signaling through different neural circuits than GLP-1 alone, potentially creating complementary effects on hunger suppression and energy expenditure. Patients with specific genetic variants in the GIPR or GLP1R genes may respond more favorably to one agent over the other, which is why genetic insights can inform therapy selection. PlexusDx uses the Precision Peptide Genetic Test to map 14 metabolic pathways and identify which receptor-activation strategy aligns best with your individual peptide genetics.

Clinical Trial Results: Weight Loss Efficacy Comparison

Ozempic (semaglutide) at maximum doses demonstrated approximately 15% body weight reduction in the SUSTAIN-6 trial over 68 weeks among patients with obesity and overweight conditions. Mounjaro (tirzepatide) achieved up to 20–22% body weight reduction in the SURMOUNT-1 and SURMOUNT-2 trials at the highest doses over comparable timeframes, suggesting numerically greater losses with dual-pathway activation. However, individual outcomes vary widely based on adherence, lifestyle factors, and underlying genetic predispositions to GLP-1 and GIP receptor signaling.

Neither medication is universally superior for all patients—response depends on your metabolic phenotype, baseline insulin sensitivity, and genetic variants that influence peptide pathways. Some individuals achieve exceptional results on semaglutide alone, while others benefit from tirzepatide's dual-agonist approach. Starting with genetic testing through PlexusDx's Precision Peptide protocol can identify your peptide-pathway profile and guide initial therapy selection before committing to a long-term regimen.

Injectable vs Oral Formulations and Administration

Ozempic is administered as a once-weekly subcutaneous injection in a prefilled pen, while tirzepatide (Mounjaro) uses the same injection frequency and device format. Both medications require weekly dosing schedules and gradual dose escalation over 4–6 weeks to reach therapeutic levels and minimize gastrointestinal side effects. PlexusDx offers compounded tirzepatide injections starting at $289/mo (or $249/mo on the 6-month plan), with your dose adjusted upward as needed without increasing your monthly cost—the pricing remains flat across all dose levels.

Oral formulations of both medications have entered clinical development, and PlexusDx now provides compounded oral tirzepatide at $349/mo (or $279/mo on the 6-month plan) for patients who prefer pill-based therapy over injections. Oral bioavailability of these peptides historically presented challenges, but newer formulation technologies are improving absorption rates and clinical outcomes. Choosing between injection and oral depends on your lifestyle preferences, injection comfort level, and how your individual physiology responds to different delivery routes.

Cost, Access, and Insurance Considerations

Brand-name Ozempic and Mounjaro carry retail prices exceeding $1,000 monthly and often require insurance approval or prior authorization, which delays access and adds administrative burden. PlexusDx provides compounded tirzepatide injections from licensed 503A compounding pharmacies at $289 per month flat, with no insurance required, no membership fees, and HSA/FSA eligibility. Patients in all 50 states can access compounded semaglutide injections starting at $189/mo (or $149/mo on the 6-month plan) through the same straightforward pricing model.

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Mounjaro or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Side Effects and Tolerability Profiles

Both semaglutide and tirzepatide commonly cause nausea, vomiting, diarrhea, and constipation during the initial titration phase, with gastrointestinal symptoms typically improving within 2–4 weeks as your body adapts. Tirzepatide carries a slightly higher incidence of nausea in early clinical trials compared to semaglutide, though the difference diminishes over time as patients reach stable maintenance doses. Starting at the lowest effective dose and titrating slowly—a practice supported by PlexusDx dosing protocols—reduces intolerable side effects and improves treatment continuation rates.

Serious adverse effects, including pancreatitis and gallbladder complications, are rare but possible with both GLP-1 and dual-agonist therapies; patients with personal or family histories of medullary thyroid cancer should avoid these medications entirely. Regular monitoring for changes in appetite, energy levels, and metabolic markers ensures your clinician can detect complications early and adjust dosing accordingly. PlexusDx recommends ongoing communication with your prescribing provider throughout treatment to optimize tolerability and efficacy.

Choosing Between Semaglutide and Tirzepatide for Your Metabolism

The choice between Ozempic and Mounjaro is not about which is universally 'better,' but rather which aligns with your genetic predispositions, medical history, weight-loss goals, and lifestyle preferences. Patients with strong family histories of type 2 diabetes or metabolic syndrome may benefit more from tirzepatide's dual GLP-1/GIP activation, given that pathway's insulin-enhancing effects. Conversely, individuals seeking a simpler, single-pathway intervention may respond well to semaglutide's proven track record across diverse populations.

PlexusDx's Precision Peptide Genetic Test identifies your peptide-pathway genetic signature across 49 key peptides and 14 metabolic pathways, removing guesswork from medication selection. Your prescribing provider can use this genetic data alongside your clinical presentation to select the therapy most likely to succeed, accelerating your path to sustainable weight loss without wasted months on suboptimal treatments.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide more effective than semaglutide for weight loss?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I switch from Ozempic to Mounjaro if one isn't working?

Yes, patients can transition between semaglutide and tirzepatide under medical supervision, though the switch typically requires a washout period and new titration schedule to minimize side effects. PlexusDx providers coordinate seamless medication changes and can reference your genetic profile to refine the new therapy's dosing strategy for faster results.

How much does compounded tirzepatide cost at PlexusDx?

Compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) flat—your dose may increase, but your price stays the same across all dose levels. PlexusDx requires no insurance, no membership fee, and is HSA/FSA eligible in all 50 states.

Are compounded semaglutide and tirzepatide as safe as brand-name versions?

PlexusDx sources all compounded medications from licensed 503A compounding pharmacies that follow strict FDA quality standards and use the same pharmaceutical-grade active ingredients as brand medications. Efficacy and safety profiles are equivalent, though you should always report side effects to your prescribing provider immediately.

What genetic variants does the Precision Peptide Genetic Test check?

No — the Precision Peptide Genetic Test does not predict your response to Mounjaro or any specific medication. It analyzes pathway-level variants (GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves